Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
FOLD is in the long-term up 367% in 10 years.
Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-40.12%||ROE||-74.29%||ROI||-61.43%|
|Current Ratio||7.19||Quick Ratio||Long Term Debt/Equity||0.07||Debt Ratio||0.2|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||4.06 M||Cash From Investing Activities||21.66 M||Cash From Operating Activities||-20.98 M||Gross Profit|
|Net Profit||-24.29 M||Operating Profit||-24.06 M||Total Assets||192.62 M||Total Current Assets||151.25 M|
|Total Current Liabilities||21.02 M||Total Debt||14.4 M||Total Liabilities||88.61 M||Total Revenue|
|High 52 week||17.09||Low 52 week||8.38||Last close||12.25||Last change||-2.62%|
|RSI||35.01||Average true range||0.62||Beta||1.18||Volume||3.52 M|
|Simple moving average 20 days||-6.53%||Simple moving average 50 days||-8.64%||Simple moving average 200 days||0.24%|
|Performance Week||-3.77%||Performance Month||-4.82%||Performance Quart||7.27%||Performance Half||13.64%|
|Performance Year||-23.72%||Performance Year-to-date||27.87%||Volatility daily||2.42%||Volatility weekly||5.4%|
|Volatility monthly||11.07%||Volatility yearly||38.34%||Relative Volume||222.44%||Average Volume||3.04 M|
|New High||New Low|
2020-05-21 14:25:26 | Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT
2020-05-19 09:47:32 | Billionaire Steven Cohen Bets Big on These 3 Stocks
2020-05-09 13:31:04 | Amicus Therapeutics Inc FOLD Q1 2020 Earnings Call Transcript
2020-05-08 11:46:06 | 7 “Strong Buy” Healthcare Stocks to Buy Now
2020-05-08 07:00:10 | Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
2020-05-07 09:25:01 | Amicus Therapeutics FOLD Reports Q1 Loss, Tops Revenue Estimates
2020-05-07 07:00:10 | Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
2020-04-30 12:33:04 | Will Amicus Therapeutics FOLD Report Negative Earnings Next Week? What You Should Know
2020-04-24 07:00:10 | Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
2020-04-13 08:42:10 | Is Amicus Therapeutics, Inc. NASDAQ:FOLD A Volatile Stock?
2020-04-01 11:30:03 | Amicus Therapeutics FOLD Up 1.1% Since Last Earnings Report: Can It Continue?
2020-03-28 20:38:10 | Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. FOLD
2020-03-22 15:58:43 | Edited Transcript of FOLD earnings conference call or presentation 2-Mar-20 1:30pm GMT
2020-03-05 07:00:10 | Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
2020-03-03 09:38:02 | Amicus' FOLD Q4 Earnings Miss Estimates, Sales Surpass
2020-03-02 08:25:01 | Amicus Therapeutics FOLD Reports Q4 Loss, Tops Revenue Estimates
2020-02-26 07:00:10 | Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
2020-02-19 07:00:10 | Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020
2020-02-17 07:43:24 | Our Take On Amicus Therapeutics, Inc.'s NASDAQ:FOLD CEO Salary
2020-01-13 07:00:10 | Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
2020-01-10 11:43:15 | 2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. FOLD
2020-01-08 10:04:03 | Amicus FOLD Provides Updates on AT-GAA for Pompe Disease
2020-01-03 09:41:02 | Amicus Progresses on Pipeline Development Amid Competition
2019-12-11 11:30:04 | Why Is Amicus Therapeutics FOLD Up 6% Since Last Earnings Report?
2019-12-05 22:53:02 | Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. FOLD Too Early
2019-12-04 09:28:02 | Amicus Therapeutics, Inc. FOLD Shares March Higher, Can It Continue?
2019-11-20 10:09:16 | Co-working space takes aim at Lake Nona
2019-11-19 15:03:08 | How to Find Cheap Buy-Ranked Stocks Trading Under $10
2019-11-18 09:24:59 | Is Amicus Therapeutics NASDAQ:FOLD A Risky Investment?
2019-11-12 18:51:32 | Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT
2019-11-12 09:52:02 | Amicus' FOLD Shares Rise on Q3 Earnings & Revenue Beat
2019-11-12 09:33:02 | Company News For Nov 12, 2019
2019-11-12 09:25:00 | Done deal: Tavistock sells land to New Jersey biotech firm
2019-11-11 08:15:01 | Amicus Therapeutics FOLD Reports Q3 Loss, Tops Revenue Estimates
2019-11-11 07:00:00 | Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
2019-11-07 11:41:16 | Bet on This Biotech Before Earnings
2019-11-07 11:15:04 | Cronos CRON to Report Q3 Earnings: What's in the Cards?
2019-11-05 11:50:04 | CannTrust CTST to Report Q3 Earnings: What's in Store?